129 related articles for article (PubMed ID: 10591805)
1. [Amifostine as protective agent in cisplatin-based chemotherapy of advanced bladder cancer].
Heidenreich A; Marx FJ; Peters HJ
Urologe A; 1999 Nov; 38(6):586-91. PubMed ID: 10591805
[TBL] [Abstract][Full Text] [Related]
2. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
Kemp G; Rose P; Lurain J; Berman M; Manetta A; Roullet B; Homesley H; Belpomme D; Glick J
J Clin Oncol; 1996 Jul; 14(7):2101-12. PubMed ID: 8683243
[TBL] [Abstract][Full Text] [Related]
3. The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
Hartmann JT; Knop S; Fels LM; van Vangerow A; Stolte H; Kanz L; Bokemeyer C
Anticancer Drugs; 2000 Jan; 11(1):1-6. PubMed ID: 10757556
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.
Hartmann JT; Fels LM; Knop S; Stolt H; Kanz L; Bokemeyer C
Invest New Drugs; 2000 Aug; 18(3):281-9. PubMed ID: 10958599
[TBL] [Abstract][Full Text] [Related]
5. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma.
Rose PG
Semin Oncol; 1996 Aug; 23(4 Suppl 8):83-9. PubMed ID: 8783673
[TBL] [Abstract][Full Text] [Related]
6. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
Tannehill SP; Mehta MP; Larson M; Storer B; Pellet J; Kinsella TJ; Schiller JH
J Clin Oncol; 1997 Aug; 15(8):2850-7. PubMed ID: 9256128
[TBL] [Abstract][Full Text] [Related]
7. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic Effect of Premedication with Intravenous Magnesium on Renal Dysfunction in Preoperative Cisplatin-Based Chemotherapy for Esophageal Cancer.
Kubo Y; Miyata H; Sugimura K; Shinno N; Ushigome H; Yanagimoto Y; Takahashi Y; Yamamoto K; Nishimura J; Wada H; Takahashi H; Yasui M; Omori T; Ohue M; Yano M
Oncology; 2019; 97(6):319-326. PubMed ID: 31553989
[TBL] [Abstract][Full Text] [Related]
10. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
Marina N; Chang KW; Malogolowkin M; London WB; Frazier AL; Womer RB; Rescorla F; Billmire DF; Davis MM; Perlman EJ; Giller R; Lauer SJ; Olson TA;
Cancer; 2005 Aug; 104(4):841-7. PubMed ID: 15999362
[TBL] [Abstract][Full Text] [Related]
11. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.
Schiller JH; Storer B; Berlin J; Wittenkeller J; Larson M; Pharo L; Larson M; Berry W
J Clin Oncol; 1996 Jun; 14(6):1913-21. PubMed ID: 8656260
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
Kuroda M; Meguro N; Maeda O; Saiki S; Kinouchi T; Usami M; Kotake T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S9-13. PubMed ID: 7527736
[TBL] [Abstract][Full Text] [Related]
13. Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder.
Maeda T; Takahashi A; Hirobe M; Honma I; Masumori N; Itoh N; Tsukamoto T
Hinyokika Kiyo; 2007 Apr; 53(4):213-9. PubMed ID: 17515069
[TBL] [Abstract][Full Text] [Related]
14. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
[TBL] [Abstract][Full Text] [Related]
15. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
Sastry J; Kellie SJ
Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
[TBL] [Abstract][Full Text] [Related]
16. [Is down-staging of advanced bladder cancer by neoadjuvant chemotherapy possible?--MVEC protocol].
Hoch V; Noll F; Schreiter F
Urologe A; 1992 Jul; 31(4):243-6. PubMed ID: 1514212
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
Hartmann JT; von Vangerow A; Fels LM; Knop S; Stolte H; Kanz L; Bokemeyer C
Br J Cancer; 2001 Feb; 84(3):313-20. PubMed ID: 11161394
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy of advanced transitional-cell carcinoma of the bladder.
Miller RS; Torti FM
Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829
[TBL] [Abstract][Full Text] [Related]
19. Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: a phase II trial.
Sousa-Escandon A; Vazquez S; Quintero-Aldana G; Picallo JA; Neira J; Garcia-Novio F; Mateo A; Rico M; Mel JR
Int J Urol; 2002 Mar; 9(3):162-6. PubMed ID: 12010328
[TBL] [Abstract][Full Text] [Related]
20. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
Saito Y; Kobayashi M; Yamada T; Kasashi K; Honma R; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Iseki K
Support Care Cancer; 2017 Feb; 25(2):481-487. PubMed ID: 27699503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
